New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2013
13:43 EDTGSK, SRPTDuchenne muscular dystrophy patients hospitalized, TheStreet says
Duchenne muscular dystrophy patients treated with drisapersen, GlaxoSmithKline's (GSK) experimental drug, have been hospitalized, according to a report by TheStreet that cites a Glaxo scientist speaking in Rome last Sunday. The report notes that Sarepta Therapeutics (SRPT) is meeting with the FDA this quarter to discuss the possibility of an accelerated approval filing for its Duchenne muscular dystrophy drug eteplirsen. Reference Link
News For GSK;SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
15:14 EDTSRPTTraveler returned from Mali being tested for Ebola in NYC, Daily News reports
Subscribe for More Information
November 19, 2014
07:52 EDTGSKInforma Business Information to hold a conference
Subscribe for More Information
November 18, 2014
09:17 EDTSRPTSarepta announces first patient dosed in Eteplirsen study
Subscribe for More Information
07:20 EDTGSKEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information
November 17, 2014
17:02 EDTGSKClovis in oncology clinical trial collaboration with GlaxoSmithKline
Subscribe for More Information
08:44 EDTSRPTNebraska Medical announces death of third Ebola patient
The Nebraska Medical Center said via Twitter, "We are sorry to announce that the 3rd Ebola patient, Dr. Martin Salia, has passed away as a result of the advanced symptoms of the disease." Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED).
05:32 EDTGSKMedidata announces collaboration with GlaxoSmithKline
Medidata (MDSO) announced the completion of a method development project conducted in partnership with GlaxoSmithKline (GSK) to evaluate the impact of unifying mobile health, or mHealth, devices with cloud-based technologies in a clinical trial setting. The joint initiative assessed the capabilities of mHealth tools and evaluated how they could be used to enable a new model for clinical trial conduct that aligns site and patient needs with faster study execution and reduced costs. The collaborative project, which took place at GSK’s Human Performance Lab, demonstrated that mHealth technologies have the power to comprehensively collect large volumes of objective data that is reliable, secure and analysis-ready, and provides real-time, continuous insight into the well being of patients. All of the data collected was audited and is compliant with FDA regulations. Additionally, the effort indicated that mobile devices can support the long-term goal of lessening the burden on patients participating in studies by streamlining routine procedures, eliminating unnecessary ones and reducing visits to clinical trial sites.
November 14, 2014
14:53 EDTGSKCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
07:14 EDTGSKAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
12:59 EDTGSKApollo plans bid for GSK mature drugs business, Reuters reports
Subscribe for More Information
November 12, 2014
17:20 EDTSRPTSarepta doses first patient in study of muscular dystrophy candidate Eteplirsen
Subscribe for More Information
09:16 EDTGSKLigand reports GlaxoSmithKline EU regulatory submission for Revolade
Subscribe for More Information
08:53 EDTGSKGlaxoSmithKline weakness creates buying opportunity, says Argus
After GlaxoSmithKline cut its near-term EPS guidance, Argus still believes that the company's deals with Novartis (NVS) should boost its EPS growth in the years ahead, likely as soon as 2015. The firm thinks the stock is a good value for long-term investors, and it keeps a Buy rating on the shares.
08:18 EDTGSKUBS to hold a conference
Subscribe for More Information
November 10, 2014
16:07 EDTGSKUBS to hold a conference
UBS European Conference is being held in London, England on November 11-12.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use